A Novel Genetic Mechanism of Caplacizumab Resistance in iTTP – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Mari Thomas et al., adding:
“Caplacizumab Resistance in Immune Thrombotic Thrombocytopenic Purpura (iTTP) Associated with VWF A1 Domain Missense Variant
This landmark first report describes caplacizumab resistance in an iTTP patient caused by a VWF A1 domain missense variant (P1266L) that impairs drug binding, revealing a novel genetic mechanism of treatment failure beyond premature therapy discontinuation.”
Title: Caplacizumab resistance in immune thrombotic thrombocytopenic purpura is associated with a von Willebrand factor A1 domain missense variant
Authors: Mari Thomas, Imogen Buckle, Adela Constantinescu-Bercu, Rens De Groot, Sabina McCann, Marie Scully
Read the Full Article on JTH
Other articles about Journal of Thrombosis and Haemostasis
-
Aug 31, 2026, 05:19Tania Ahuja: Apixaban in Abdominal Transplant Patients
-
Aug 31, 2026, 04:28Reza Hafidz Irawan։ Automated Antibody Titration With Erytra Eflexis
-
Aug 31, 2026, 04:17Safa Chenganath: Stenosis vs Thrombosis – Hemodialysis Vascular Access
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session
-
Aug 30, 2026, 17:02David McGlasson: A 2020 Article Reaches 8,000 Reads